Calithera Biosciences, Inc. (CALA) Bundle
A Brief History of Calithera Biosciences, Inc. (CALA)
Company Formation and Early Years
Calithera Biosciences, Inc. was founded in 2010, focusing on the development of novel therapies in oncology and other disease areas. The company went public on NASDAQ under the ticker symbol CALA in 2015.
Key Developments and Product Pipeline
Calithera's lead product candidate, CB-839, is an oral inhibitor of the enzyme glutaminase. The drug is designed for treating solid tumors, particularly renal cell carcinoma. In 2020, Calithera reported progress in clinical trials, with Phase 1 and Phase 2 studies underway.
| Year | Development Stage | Product | Status |
|---|---|---|---|
| 2015 | Initial Public Offering | CALA | Listed on NASDAQ |
| 2019 | Phase 1 | CB-839 | Renal Cell Carcinoma |
| 2020 | Phase 2 | CB-839 | Combination with Nivolumab |
| 2022 | Phase 3 | CB-839 | Frontal Cortex Trials |
Financial Performance
As of the second quarter of 2023, Calithera reported a total revenue of $3.1 million, primarily from collaboration and license agreements. The company recorded a net loss of approximately $15.2 million.
Market Position and Collaborations
Calithera has established collaborations with notable pharmaceutical companies, including Amgen and Merck. These partnerships have bolstered its research capabilities and market presence.
| Year | Collaborator | Purpose | Financial Terms |
|---|---|---|---|
| 2018 | Amgen | Research Collaboration | $10 million upfront |
| 2021 | Merck | Clinical Development | $15 million equity investment |
Recent Updates and Future Directions
In 2023, Calithera announced advancements in its pipeline, particularly with CB-839 showing promising efficacy in combination therapies. The company aims to expand its portfolio with additional studies focusing on other malignancies.
Stock Performance
As of October 2023, Calithera's stock was trading at approximately $0.75 per share, reflecting a market capitalization of around $45 million. The stock has seen fluctuations, influenced by clinical trial results and market conditions.
| Date | Stock Price ($) | Market Capitalization ($ millions) | Change (%) |
|---|---|---|---|
| Jan 2023 | 1.25 | 75 | -12 |
| Apr 2023 | 0.90 | 54 | -28 |
| Oct 2023 | 0.75 | 45 | -17.5 |
A Who Owns Calithera Biosciences, Inc. (CALA)
Ownership Structure
Ownership Structure
The ownership of Calithera Biosciences, Inc. (CALA) is comprised mainly of institutional investors, corporate insiders, and retail investors. As of the most recent filings, the largest shareholders include:
| Shareholder Type | Ownership Percentage | Number of Shares Owned |
|---|---|---|
| Institutional Investors | 77.50% | 22,537,095 |
| Corporate Insiders | 6.90% | 2,029,450 |
| Retail Investors | 15.60% | 4,634,455 |
Top Institutional Shareholders
As of the latest data, the following institutional investors hold significant stakes in Calithera Biosciences:
| Institution Name | Ownership Percentage | Number of Shares Owned |
|---|---|---|
| BlackRock, Inc. | 12.40% | 3,630,000 |
| The Vanguard Group, Inc. | 8.90% | 2,615,000 |
| Wellington Management Co. LLP | 6.50% | 1,915,000 |
| Invesco Ltd. | 5.10% | 1,500,000 |
| Geode Capital Management, LLC | 3.50% | 1,020,000 |
Corporate Insiders
Key corporate insiders holding shares in Calithera Biosciences include:
| Name | Position | Shares Owned |
|---|---|---|
| Dr. Susan M. Cain | Chief Executive Officer | 1,000,000 |
| Michael E. O'Neal | Chief Financial Officer | 500,000 |
| Dr. R. Scott G. Henson | Chief Scientific Officer | 529,450 |
Recent Share Price Data
As of the latest trading session, the stock price of Calithera Biosciences was:
| Date | Opening Price | Closing Price | Market Capitalization |
|---|---|---|---|
| October 20, 2023 | $0.45 | $0.47 | $38.45 Million |
Stock Performance
Over the past year, the performance of Calithera Biosciences has been as follows:
| Metric | Value |
|---|---|
| 52-Week High | $1.20 |
| 52-Week Low | $0.30 |
| Year-to-Date Change | -25% |
Future Ownership Trends
Projected trends suggest that as the biotechnology sector evolves, Calithera may experience shifts in its ownership structure influenced by:
- Emerging institutional investors
- Potential acquisitions or mergers
- Changes in retail investor interest
Continued analysis of shareholder reports and market behavior will provide further insights into the ownership dynamics of Calithera Biosciences.
Calithera Biosciences, Inc. (CALA) Mission Statement
Company Overview
Company Overview
Calithera Biosciences, Inc. (CALA) is a clinical-stage biopharmaceutical company focused on discovering and developing novel drugs that target cancer metabolism. The mission statement reflects its commitment to improving the lives of cancer patients by advancing innovative therapies.
Core Mission Statement
The mission of Calithera Biosciences is to develop and deliver innovative therapies that target key aspects of cancer metabolism with the aim of improving patient outcomes and addressing significant unmet medical needs in oncology.
Key Objectives
- Develop a pipeline of therapies focused on metabolic pathways in cancer.
- Establish partnerships with leading research institutions to foster innovation.
- Enhance patient quality of life through targeted therapeutic approaches.
- Achieve regulatory milestones that facilitate drug development and approval.
Funding and Financial Overview
- Develop a pipeline of therapies focused on metabolic pathways in cancer.
- Establish partnerships with leading research institutions to foster innovation.
- Enhance patient quality of life through targeted therapeutic approaches.
- Achieve regulatory milestones that facilitate drug development and approval.
Funding and Financial Overview
Calithera Biosciences reported a cash position of $56.6 million as of the end of the second quarter of 2023. The company’s net loss for the same period was approximately $4.3 million.
Recent Developments
In July 2023, Calithera announced a strategic alliance with a leading pharmaceutical entity, leading to an upfront payment of $10 million and potential milestone payments up to $50 million.
Product Pipeline
The company's pipeline includes CAL-001, CAL-015, and CAL-016, all targeting distinct metabolic pathways in various cancers.
| Product Name | Indication | Development Stage | Projected Milestone |
|---|---|---|---|
| CAL-001 | Non-Small Cell Lung Cancer | Phase 2 | Q4 2023 |
| CAL-015 | Renal Cell Carcinoma | Phase 1 | Q1 2024 |
| CAL-016 | Breast Cancer | Preclinical | 2025 |
Market Impact
According to market analysis, the global cancer therapeutics market was valued at approximately $150 billion in 2022 and is projected to reach $250 billion by 2030, driven by advancements in drug development and increasing prevalence of cancer.
Strategic Vision
Calithera aims to position itself as a leader in cancer metabolism therapies through innovative research, strategic partnerships, and a commitment to addressing pivotal areas in oncology.
How Calithera Biosciences, Inc. (CALA) Works
Company Overview
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on discovering and developing novel cancer therapies targeting fundamental metabolic pathways in tumors. Their current pipeline includes various candidates for the treatment of solid tumors and hematologic malignancies.
Business Model
The business model of Calithera revolves around the research and development of innovative cancer therapeutics based on insights into tumor metabolism.
- Focus on unique approaches in oncology drug development.
- Collaboration with academic and industry partners for research.
- Funding through public offerings and partnerships.
Current Pipeline
As of the latest quarterly report, Calithera's pipeline includes:
| Product Candidate | Indication | Phase | Trial Status |
|---|---|---|---|
| CB-839 | Renal Cell Carcinoma | Phase 2 | Ongoing |
| CB-668 | Non-Small Cell Lung Cancer | Phase 1 | Ongoing |
| CB-103 | Solid Tumors | Phase 1 | Ongoing |
Financial Performance
For the fiscal year ending December 31, 2022, Calithera reported the following financial metrics:
| Financial Metric | Amount (in millions USD) |
|---|---|
| Total Revenue | 5.2 |
| Net Loss | 32.1 |
| Research and Development Expenses | 22.4 |
| Cash and Cash Equivalents | 40.3 |
Recent Developments
Recent corporate developments include:
- In March 2023, Calithera announced data from their ongoing clinical trials for CB-839.
- Partnerships with other biotech firms for combination therapies.
- Continuous updates on clinical trial results expected throughout 2023.
Market Position
As of October 2023, Calithera Biosciences has a market capitalization of approximately $130 million. Their stock (CALA) has seen fluctuations typically associated with clinical trial announcements and overall market conditions.
Investor Engagement
Calithera engages investors through:
- Quarterly earnings calls and annual investor meetings.
- Regular updates on clinical trial progress.
- Transparency in financial reporting.
How Calithera Biosciences, Inc. (CALA) Makes Money
Revenue Streams
Calithera Biosciences, Inc. primarily generates revenue through:
- Licensing agreements
- Collaborative research and development partnerships
- Product sales
Licensing Agreements
Calithera has entered into various licensing agreements that allow it to receive milestone payments and royalties. As of 2023, the company reported receiving over $11 million in licensing fees associated with its partnered programs.
Collaborative Research and Development Partnerships
The company collaborates with larger pharmaceutical firms for the development of its drugs. In 2022, Calithera announced a collaboration with Merck & Co. for a program that could yield up to $162 million in potential milestone payments, including upfront payments.
Product Sales
Calithera's lead product, CB-839, is in various stages of clinical trials. The revenue from product sales, however, is still minimal as the drug is not yet commercially available. The projected market value for CB-839, if approved, is forecasted to reach $500 million annually.
Financial Overview
As of Q3 2023, Calithera reported:
- Cash and cash equivalents: $45 million
- Total assets: $75 million
- Liabilities: $30 million
- Net loss for the quarter: $8 million
Research and Development Expenses
Research and development (R&D) expenses for Calithera are significant. In 2022, R&D expenses amounted to approximately $38 million, accounting for over 60% of the total operating expenses.
Revenue Growth
In 2022, Calithera saw a revenue growth of approximately 5% compared to 2021, largely driven by licensing agreements and collaborative partnerships.
Table of Financial Data
| Year | Revenue ($ Millions) | Net Loss ($ Millions) | R&D Expenses ($ Millions) | Cash & Equivalents ($ Millions) |
|---|---|---|---|---|
| 2021 | 10 | (7) | 35 | 50 |
| 2022 | 10.5 | (8) | 38 | 40 |
| 2023 (Q3) | 8 | (8) | 30 | 45 |
Future Revenue Potential
As of 2023, Calithera is focusing on key product candidates in oncology. If CB-839 gains regulatory approval, projected revenues could place the company among significant players in the oncology sector.
Conclusion on Financial Position
As of Q3 2023, Calithera stands at a crossroads of potential with numerous partnerships and a promising drug pipeline, balancing its financial position with ongoing investment in research and development.
Calithera Biosciences, Inc. (CALA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support